# OnCo record eprenetapopt (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eprenetapopt/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eprenetapopt" ;
  schema:name "Eprenetapopt"@en ;
  schema:description "Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020."@en ;
  schema:url <https://onco.cc/drugs/eprenetapopt/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Eprenetapopt> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27294965> ;
  schema:citation <https://www.globenewswire.com/news-release/2020/12/28/2150865/0/en/Aprea-Therapeutics-Announces-Results-of-Primary-Endpoint-from-Phase-3-Trial-of-Eprenetapopt-in-TP53-Mutant-Myelodysplastic-Syndromes-MDS.html> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:wrong-target" ;
  onco:modality "Small molecule (p53 reactivator)" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:targets <https://onco.cc/targets/tp53/> ;
  onco:companies <https://onco.cc/companies/aprea-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/p53-cell-cycle/> .